Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-AML Cells

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by a block in differentiation and uncontrolled proliferation. FLT3 is a commonly mutated gene found in AML patients. In clinical trials, the presence of a FLT3-ITD mutation significantly correlates with an increased risk of relapse and dismal overall survival. Therefore, activated FLT3 is a promising molecular target for AML therapies. In this study, we have shown that green tea polyphenols including (−)-epigallocatechin-3-gallate (EGCG), (−)-epigallocatechin (EGC), and (−)-epicatechin-3-gallate (ECG) suppress the proliferation of AML cells. Interestingly, EGCG, EGC and ECG showed the inhibition of FLT3 expression in cell lines harboring FLT3 mutations. In the THP-1 cells harboring FLT3 wild-type, EGCG showed the suppression of cell proliferation but did not suppress the expression of FLT3 even at the concentration that suppress 100% cell proliferation. Moreover, EGCG-, EGC-and ECG-treated cells showed the suppression of MAPK, AKT and STAT5 phosphorylation. Altogether, we suggest that green tea polyphenols could serve as reagents for treatment or prevention of leukemia harboring FLT3 mutations.

About the Authors:

Bui Thi Kim Ly

Affiliation: Department of Medical Genome Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan

Hoang Thanh Chi

* E-mail: [email protected]

Affiliation: Department of Medical Genome Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan

Makoto Yamagishi

Affiliation: Department of Medical Genome Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan

Yasuhiko Kano

Affiliation: Division of Hematology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan

Yukihiko Hara

Affiliation: Tea Solution, Hara Office Inc., Sumida-ku, Tokyo, Japan

Kazumi Nakano

Affiliation: Department of Medical Genome Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan

Yuko Sato

Affiliation: The Japanese Red Cross College of Nursing, Shibuya-ku, Tokyo, Japan

Toshiki Watanabe

Affiliation: Department of Medical Genome Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan

Introduction

Acute myeloid leukemia (AML) is the most common type of adult leukemia, affecting mostly elder people and its incidence increases with the age. It is an aggressive disease that involves rapid growth of abnormal leukemic cells in the bone marrow, resulting in failure of production of normal blood cells [1]. FLT3 (Fms-like tyrosine kinase 3) is a commonly mutated gene found in AML patients with the approximately 5–30% of the cases of AML [2]. FLT3 is one of the members of the subclass III of Receptor Tyrosine Kinase (RTK) family and is normally expressed on the cell surface of hematopoietic progenitor cells but expression is lost upon cell maturation [3]. A very high expression of FLT3 has been found in around 70–100% AML patients that usually associate with a worse prognosis [4], [5].

FLT3 mutations are predominantly detected in juxtamembrane domain (JMD) [6] and in tyrosine kinase domains (TKD) including the in-frame internal tandem duplication (FLT3-ITDs) [6], the point mutation [2], [7] and the insertion of six bases [8]. FLT3-ITDs have been found mostly in JMD [6] and few cases in TKD [9] with the approximation of 15–35% of AML [2], [10], [11], [12], whereas FLT3 point mutations was predominantly found in activation loop of TKD (at D835 [7] and I836 position [2]) but rare in JMD [13] with approximately 5–10% of AML patients [2], [10], [11], [12]. The last mutation form was the insertion of a glycine and a serine between amino acids 840 and 841 of FLT3 [8]. FLT3 mutations result in a ligand-independent receptor dimerization, phosphorylation and constitutive activation of downstream signaling molecules including the RAS/RAF/MEK/ERK kinases, PI3-kinase and STAT5 kinases [14], [15], [16], [17]. In clinical, the presence of a FLT3-ITD mutation significantly correlates with an increased risk of relapse and dismal overall survival with the median survival after the first relapse has been reported to be ≤5 months [18], [19]. Therefore, activated FLT3 is a promising molecular target for AML therapies.

Currently, several small molecule FLT3-tyrosine kinase inhibitors (FLT3-TKIs) have been developed and examined in AML patients as single agents or in combination with chemotherapy. Up to now, six oral FLT3 inhibitors, including CEP-701, PKC412, BAY 43-9006, SU11248, MLN-518 and KW-2449, the i.v. compound SU5416 and AC220 have been investigated as monotherapy in clinical trials. In addition, FLT3-directed antibody therapy (IMC-EB10) is currently being investigated in a phase 1 clinical trial. FLT3-TKI monotherapy has been proven to efficiently target FLT3-mutated AML blasts [20]. However, approval of these agents for FLT3-associated diseases is still challenging, which was suspected to be due to the failure to fully inhibit FLT3 in tumors and undesirable drug properties [21].

In this study, we evaluated the anti-cancer effect of green tea polyphenols including (−)-epigallocatechin-3-gallate (EGCG), (−)-epigallocatechin (EGC), (−)-epicatechin-3-gallate (ECG), and (+)-Catechin (C) in a group of AML cell lines harboring FLT3 mutation. It is well documented that polyphenols of green tea show anti-cancer effects on many types of human malignancies, but not to their normal counterpart [22]. Currently, green tea is now developing as a cancer preventive drug in the USA and Europe [23], [24]. Our results show that EGCG, EGC and ECG treatment disrupts the association of Hsp90 with FLT3-ITD and results in reduced levels of FLT3 expression in AML harboring mutated FLT3.

Materials and Methods

2.1. Cell Lines, Culture Conditions

Experiments were conducted using four human leukemia cell lines: two sister cell lines MOLM-13 and MOLM-14 that were established from a patient with acute monocytic leukemia (M5a) harboring t(9;11) [25]; MV4-11 from a patient with AML carrying t(4;11) [26] and KOCL-48 from an infant leukemic patient carrying t(4;11) [27].

In MOLM-13 and MOLM-14 cells, two mutations within FLT3 exon 14 were detected: ITD of 21 bps corresponding to codons Phe594-Asp600 and a novel missense nucleotide substitution at the codon 599 (Tyr599Phe) [28], [29]. Two kinds of mutations were located on the same allele [29]. In MV4-11 cells, there are an ITDs of 30 bps within FLT3 exon 14 corresponding to codons Tyr591-Asp600, and a Tyr591His mutation [28], [29]. In KOCL-48 cell line, only FLT3-Asp835Glu mutation was detected [28].

The cell line THP-1 came from the peripheral blood of a one-year old infant male with monocytic AML [30]. They do not contain a known FLT3 mutation and have high endogenous wild-type FLT3 (FLT3-WT) expression. THP-1 cells will be used as a negative control in this study.

The cells were grown in RPMI 1640 medium (Sigma-Aldrich, Japan K.K., Tokyo, Japan) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (JRH Biosciences, Lenexa, KS, USA), 100 IU/ml penicillin, and 0.1 mg/ml streptomycin (Nakalai Tesque, Kyoto, Japan) in a humidified incubator of 5% CO2 at 37°C.

2.2. Reagents

Reagents were obtained as follows: EGCG, EGC, ECG, and C (purified powder) were generously gifted by one of us Dr. Yukihiko Hara (Japan), PKC412 was purchased from Sigma-Aldrich Japan K.K. (Tokyo, Japan) and 17-allylamino-17-desmethoxygeldanamycin (17-AAG) was purchased from Calbiochem (Darmstadt, Germany). All reagents were dissolved in dimethylsulfoxide (DMSO) (Wako Pure. Chemical Industries, Osaka, Japan). Controlled cells were cultured with the same concentration of carrier DMSO as used in the highest dose of reagents. The concentration of DMSO was kept under 0.1% throughout all the experiments to avoid its cytotoxicity.

2.3. Cell Proliferation Assays

Cell proliferation was determined by trypan blue dye exclusion test as described previously [31]. Briefly, cells were seeded in 6-well plates at a density of 1×105 cells/ml in the presence of different concentrations of EGCG, EGC, ECG and C for 72 hours. After the treatment, 10 µl of the cell suspension was mixed with 10 µl of 0.4% trypan blue, and alive cells were counted manually using a hemacytometer. Results were calculated as the percentage of the values measured when cells were grown in the absence of reagents.

2.4. Western Blot Analysis

Cells were plated onto 10 cm dishes at a density of 1×105 cells/ml in the presence of various concentrations of reagents. After incubation for indicated durations, cells were collected and washed twice with PBS (−). Cells were then dissolved in a protein lysis buffer containing 5 mM EDTA, 50 mM NaF, 10 mM Na2H2P2O7, 0.01% Triton X-100, 5 mM HEPES, 150 mM NaCl, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and 75 µg/mL aprotinin on ice for 30 min with brief vortex of 4 times with every 10 min. After centrifugation at 13,000 rpm at 4°C for 10 min, total cell lysates were collected. Protein samples were electrophoresed through a polyacrylamide gel and transferred to a Hypond-P membrane (Amersham, Buckinghamshire, UK) by electro-blotting. After washing, the membrane was probed with antibodies and antibody-binding was detected using BCIP/NBT substrate (Promega). The following antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA): FLT-3/FLK-2 (S-18) (sc-480), STAT5 (C-17) (sc-835) and survivin (sc-17779). Anti-actin (A2066) was from Sigma-Aldrich. p44/42 MAPK (Erk1/2), phospho-p44/42 MAPK (Thr202/Tyr204), AKT, phospho-AKT (Ser473), phospho-STAT5 (Tyr694), caspase-3, caspase-9 (C9) and XIAP antibodies were from Cell Signaling Technology Japan (Tokyo, Japan). Anti-PARP antibody was from WAKO Chemicals (Osaka, Japan).

2.5. Co-immunoprecipitation

For immunoprecipitation (IP), MOLM-13 cells were treated with EGCG, EGC or ECG for 8 hours and then harvested. Cells were lysed as indicated above. Then, 500 µg of protein total cell lysates were immunoprecipitated with anti-Hsp90 (Santa Cruz, CA, USA) overnight at 4°C. Protein G Sepharose 4 Fast Flow (Amersham Pharmacia Biosciences, Tokyo, Japan) was then added for 2 hours. The immunoprecipitates were washed three times with Tris buffered saline-Tween. The bound proteins were resolved by SDS-PAGE and analyzed by Western blotting.

2.6. Determination of Apoptosis

MOLM-14 cells were treated with EGCG, EGC or ECG for 16 hours. The apoptotic cell was evaluated by PE Annexin V (BD PharMingen) and analyzed by FACS Calibur (Becton, Dickinson). Collected data were analyzed by FlowJo software (Tree Star).

2.7. Isobologram

The dose-response interactions between EGCG and PKC412 on the MOLM-13, MOLM-14, MV4-11 and KOCL-48 cells were evaluated at the IC50 level by the isobologram of Steel and Peckham [32]. The IC50 was defined as the concentration of the reagent that produced 50% cell growth inhibition. The concept of the isobologram has been described in detail elsewhere [32]. We used this isobologram because this method can cope with any agents with unclear cytotoxic mechanisms and a variety of dose-response curves of anticancer agents [32].

2.8. Statistical Analysis

Data for isobologram were analyzed as described elsewhere [33]. When the observed data points of the combinations mainly fell in the area of supraadditivity or in the areas of subadditivity and protection, i.e., the mean value of the observed data was smaller than that of the predicted minimum values or larger than that of the predicted maximum values, the combinations were considered to have a synergistic or antagonistic effect, respectively. To determine whether the condition of synergism (or antagonism) truly existed, a statistical analysis was performed. The Wilcoxon signed-ranks test was used for comparing the observed data with the predicted minimum (or maximum) values for additive effects, which were closest to the observed data. Probability (P) values <0.05 were considered significant. Combinations with P≥0.05 were regarded as indicating additive to synergistic (or additive to antagonistic) effects. The other data were analyzed by Student’s t test.

Results

3.1. Growth-inhibitory Effect of EGCG, EGC, ECG and C on FLT3 Mutated-AML Cells

To test the inhibitory effect of EGCG, EGC, ECG and C on the growth of AML cell lines, MOLM13, MOLM14, MV4-11 and KOCL-48 cells were incubated either with the carrier DMSO alone (control) or with different concentrations of reagents for 72 hours. Cell proliferations were evaluated using the trypan blue exclusion test. The result showed that EGCG, EGC and ECG significantly inhibited the cell proliferation of MOLM-13, MOLM-14, MV4-11 and KOCL-48 cells in a dose-dependent manner (Fig. 1 A, B and C). Whereas, the growth-inhibition effect of (+)-Catechin on these cells was less sensitive than others (Figure 1D). Altogether, green tea polyphenols showed the anti-proliferation effects on AML cells.

[Figure omitted. See PDF.]

Figure 1. Effect of EGCG, EGC, ECG and C on cell proliferation of MOLM-13, MOLM-14, MV4-11 and KOCL-48 cell lines.

MOLM-13, MOLM-14, MV4-11, KOCL-48 and THP-1 cells at a density of 1×105 cells/ml were treated with indicated concentration of EGCG, EGC, ECG, C or DMSO alone as control for 72 hours. The number of alive cells was counted after trypan blue exclusion test. Results were calculated as the percentage of the control values.

https://doi.org/10.1371/journal.pone.0066378.g001

3.2. Down-regulation of FLT3 Expression and its Downstream Molecules in EGCG-Treated AML Cells

To address the mechanism of the EGCG-mediated growth inhibition in FLT3 mutated-AML cells, we analyzed the expression of FLT3 protein in these cells treated with or without EGCG by western blotting. Interestingly, the expression level of FLT3 protein was significantly decreased after 8 hours exposure of MOLM-13, MOLM-14, MV4-11 and KOCL-48 cells (FLT3 mutated cells) to different concentrations of EGCG (Fig. 2, the first row). However, In THP-1 cells (FLT3-WT cells), the level of FLT3 expression did not change even at high EGCG concentration treatment (180 µM) (Fig. 2, the first row). The data suggested that EGCG specifically targets mutant FLT3 rather than wild-type FLT3.

[Figure omitted. See PDF.]

Figure 2. Down-regulation of FLT3 expression and its downstream molecules in EGCG-treated AML cells.

MOLM-13, MOLM-14, MV4-11, KOCL-48 and THP-1 cells at a density of 1×105 cells/ml were treated with indicated concentration of EGCG or DMSO alone as control for 8 hours. Total cell lysates were subjected to western blot analysis with indicated antibodies.

https://doi.org/10.1371/journal.pone.0066378.g002

We reasoned that the down-regulation of FLT3 expression would lead to inhibition of its activity, subsequently suppress the activity of its down-stream molecules. To make it clear, we measured the activity of MAPK, AKT and STAT5 in MOLM-13, MOLM-14, MV4-11, KOCL-48 and THP-1 cells treated with or without EGCG. The inhibitions of MAPK, AKT and STAT5 activity (p-MARK, p-AKT and p-STAT5) were observed in MOLM-13, MOLM-14, MV4-11 and KOCL-48 cells after 8 hours incubation with EGCG (Fig. 2). Although EGCG caused the suppression of cell growth in THP-1 cells (IC50 ≈ 60 µM EGCG, Fig. 1A), only activity of MAPK but not AKT and STAT5 was decreased at very high concentration of EGCG (180 µM) (Fig. 2).

3.3. Down-regulation of FLT3 Expression and its Downstream Molecules in EGC- and ECG-treated AML Cells

To check whether EGC and ECG suppress the expression of FLT3, MOLM-13, MOLM-14, MV4-11 and KOCL-48 cells were treated with 100 µM EGC or 100 or 200 µM ECG for 8 hours. Western blot was performed to analyze the expression of FLT3. EGC-treated cells showed not only the suppression of FLT3, but also the suppression of phosphorylation of MAPK, AKT and STAT5 (Fig. 3). Similarly, the suppression of FLT3 expression and phosphorylation of its downstream molecules were also observed in ECG-treated cells (Fig. 4).

[Figure omitted. See PDF.]

Figure 3. Down-regulation of FLT3 expression and its downstream molecules in EGC-treated AML cells.

MOLM-13, MOLM-14, MV4-11 and KOCL-48 cells at a density of 1×105 cells/ml were treated with indicated concentration of EGC or DMSO alone as control for 8 hours. Total cell lysates were subjected to western blot analysis with indicated antibodies.

https://doi.org/10.1371/journal.pone.0066378.g003

[Figure omitted. See PDF.]

Figure 4. Down-regulation of FLT3 expression and its downstream molecules in ECG-treated AML cells.

MOLM-13, MOLM-14, MV4-11 and KOCL-48 cells at a density of 1×105 cells/ml were treated with indicated concentration of ECG or DMSO alone as control for 8 hours. Total cell lysates were subjected to western blot analysis with indicated antibodies.

https://doi.org/10.1371/journal.pone.0066378.g004

3.4. EGCG, EGC and ECG Suppressed FLT3 Expression through Hsp90

EGCG has been demonstrated to be an inhibitor of Hsp-90 [34]. Moreover, recently FLT3-ITD but not FLT3-WT has been shown as a client protein of Hsp-90 [35], [36]. Thus it could be assumed that mutant FLT3 expression is suppressed by EGCG treatment might through inhibition of Hsp-90. To confirm this hypothesis, total cell lysates of MOLM-13 and THP-1 cells after EGCG treatment were collected and immunoprecipitated with indicated anti-body as shown in Figure 5A. The results of immunoprecipitation showed that only FLT3-ITD could physically interact with Hsp-90 but not FLT-WT (Fig. 5A lane 3 and 5). In addition, EGCG treatment disrupts the association of Hsp90 with FLT3-ITD and results in reduced levels of FLT3 expression (Fig. 5A lane 4). Similar results are observed in EGC-, and ECG-treated MOLM-13 cells (Fig. 5B) suggesting that mechanism of EGC and ECG on suppression of FLT3 expression might through inhibit the activity of Hsp-90.

[Figure omitted. See PDF.]

Figure 5. EGCG, EGC and ECG suppressed FLT3 expression through Hsp90.

MOLM-13 cells at a density of 1×105 cells/ml were treated with 60 µM EGCG (A, lane 4), 100 µM EGC, 200 µM ECG (B, lane 2, 4) or DMSO alone as control for 8 hours. Total cell lysates were immunoprecipitated with anti-Hsp90. Precipitated protein were subjected to western blot analysis with anti-FLT3 and anti Hsp90. MOLM-13 cells treated with 2 µM 17-AAG was used as control (A, lane 2).

https://doi.org/10.1371/journal.pone.0066378.g005

3.5. EGCG, EGC and ECG Induced Apoptosis in FLT3 Mutated-AML Cells

Next, we demonstrated that EGCG, EGC and ECG induced apoptosis in FLT3 mutated cell lines. We have checked the appearance of some apoptotic markers in MOLM-14 cells after EGCG, EGC or ECG treatment by western blot. The bands of cleaved-caspase-9, cleaved-caspase-3 and cleaved-PARP were observed after 8 hours incubated with EGCG, EGC or ECG (Fig. 6A). Moreover, EGCG, EGC or ECG treatment showed the inhibition of the expression of anti-apoptotic molecules such as survivin and XIAP in MOLM-14 cells (Fig. 6A).

[Figure omitted. See PDF.]

Figure 6. EGCG, EGC and ECG induced apoptosis in MOLM-14 cells.

MOLM-14 cells at a density of 1×105 cells/ml were treated with 60 µM EGCG, 100 µM EGC, 200 µM ECG or DMSO alone as control for 16 hours. Total cell lysates were subjected to western blot analysis with indicated antibodies (A) or staining with PE-Annexin V and analyzed by FACS Calibur. Collected data were analyzed by FlowJo software (B).

https://doi.org/10.1371/journal.pone.0066378.g006

The results from PE-Annexin V staining that shown in figure 6B indicated that EGCG, EGC and ECG induce apoptosis in MOLM-14 cells treated with EGCG, EGC or ECG. Overall, the EGCG-, EGC- or ECG- induced cell death in MOLM-14 is apoptosis.

3.6. Cytotoxic Effects of EGCG in Combination with PKC412

EGCG is one of the most studied polyphenol of green tea and shows the strongest anti-cancer effect compared to other polyphenols of green tea (Fig. 1). In this study, we evaluated the combination effect of EGCG and PKC412. Interestingly, the results showed that the combination of EGCG and PKC412 treatment strongly suppressed cell growth in MOLM-13, KOCL-48, MV4-11 and MOLM-14 cells compared to EGCG or PKC412 treatment (Fig. 7). However, the combined effects of simultaneous exposure to these drugs differed among MOLM-13, MOLM-14 and KOCL-48, MV4-11 cell lines. In MOLM-13 and MOLM-14 cells, the combined data points fell within the envelope of additivity. The mean value of the data (0.423 and 0.414 respectively) was larger than that of the predicted minimum data (0.379 and 0.121 respectively) and smaller than that of the predicted maximum data for an additive effect (0.766 and 0.549 respectively; Table 1), indicating that simultaneous exposure to EGCG and PKC412 produced an additive effect. In KOCL-48 and MV4-11 cells, the combined data points fell mainly in the area of subadditivity, and the mean values of the observed data (0.887 and 0.803 respectively) were larger than those of the predicted maximum additive data (0.410 and 0.579 respectively; Table 1) which were regarded as antagonism effect.

[Figure omitted. See PDF.]

Figure 7. Isobolograms of simultaneous exposure to EGCG and PKC412 in MOLM-13, MOLM-14, MV4-11 and KOCL-48 cell lines.

The isobolograms shown are representative of at least three independent experiments. Each point represents the mean value of at least three independent experiments. The combination of EGCG with PKC412 showed additive effect (MOLM-13 and MOLM-14) and antagonism effect (MV4-11 and KOCL-48).

https://doi.org/10.1371/journal.pone.0066378.g007

[Figure omitted. See PDF.]

Table 1. Mean values of observed data and predicted minimum and maximum values of the combination of EGCG and PKC412.

https://doi.org/10.1371/journal.pone.0066378.t001

Discussion

It is well documented that polyphenols of green tea, used as a beverage for over 5,000 years, have anti-cancer effects on many types of human malignancies, but not to their normal counterpart [22]. So far, we have demonstrated that EGCG suppressed the cell proliferation and caused apoptotic cell death in GIST cells by inhibition of KIT activity [31]. In this work, we have reported that polyphenols of green tea caused apoptotic cell death in FLT3-mutated cell lines (Fig. 6) by suppressing the expression of FLT3 and ultimately suppressing the activity of AKT, MAPK and STAT5 (Fig. 2, 3 and 4).

Recent studies indicated that RTKs are one of the critical targets of EGCG to inhibit cancer cell growth. The previous studies provided evidences that EGCG inhibited the activation or expression of some RTKs including epidermal growth factor receptor (EGFR) [37], human epidermal growth factor receptor 2 (HER2), HER3 [38], [39], vascular endothelial growth factor receptor (VEGFR) [40], platelet derived growth factor receptor (PDGFR) [41], fibroblast growth factor receptors (FGFR) [37], insulin-like growth factor 1 receptor (IGF-1R) [42], [43] and KIT [31]. In this report, we showed that EGCG, EGC and ECG suppressed the FLT3 expression (Fig. 2, 3 and 4) in cell lines harboring FLT3 mutation but not in THP-1 cells that carrying FLT3 wild-type.

One of the hypothesizes that can be explains for the difference effect of EGCG on FLT3 WT and FLT3 mutant expression would be through the mediator heat shock protein 90 (Hsp90). Hsp90, a highly abundant molecular chaperone in the stress response, assists maturation of more than 200 proteins, which include transmembrane tyrosine kinases (Her-2, EGFR), metastable signaling proteins (Akt, K-ras, Raf-1), mutated signaling proteins (p53, v-Src), chimeric signaling proteins (Bcr-Abl), cell cycle regulators (Cdk4, Cdk6), and steroid receptors (androgen, estrogen, and progesterone receptors) [44], [45], [46], [47], [48]. Both the N- and C-terminal domain of Hsp90 contains specific ATP binding pockets [49], [50]. Hsp90 dimerizes through its C-terminal end. Upon ATP binding, the two N-termini of the dimer associate to form a molecular “clamp” with a client protein to exert its chaperone function [51], [52]. Previous studies show that FLT3-ITD but not FLT3-WT is a client protein of Hsp90 in murine tranfected 32D cell lines [35] and primary AML cells [36].

Recently, EGCG has been demonstrated as inhibitor of Hsp90. EGCG acts by binding at or near a C-terminal ATP binding site to inhibit dimerization and promote an Hsp90 conformation that interferes with its chaperone activity for a client protein [34]. In the same year, another group also reported that EGCG inhibits Hsp90 function by impairing Hsp90 association with cochaperones including Hsc70 and p23 in pancreatic cancer cell line Mia Paca-2 [53]. In 2010, Tran et al. reported that in MCF-7 human breast cancer cells, EGCG specifically inhibited the expression of Hsp90 by inhibiting the promoter activity of Hsp90. However, in this study, we did not observed the decrease of Hsp90 expression after 8 hours treated MOLM-13, MOLM-14, MV4-11, KOCL-48 and THP-1 cells with 60 µM EGCG (data not shown). We hypothesized that the suppression of mutant-FLT3 expression by EGCG could be mediated through Hsp90, we confirmed this hypothesis in figure 5A. Base on these confirming data, we explained why EGCG just exerted its inhibition effect on FLT3-ITD but not FLT3-WT. Moreover, we at the first time suggest that others polyphenols including EGC and ECG might also suppressed FLT3 expression through inhibition of Hsp90 function by the same way as EGCG did (Fig. 5B).

One of the effective strategies for treating AML patients with FLT3 mutations is combination of drugs that have different mechanism of pharmaceutical action. In this study, we combined EGCG with PKC412 to check their combination effect on FLT3 mutated cell lines. The concentration of both two drugs are significantly reduced (Fig. 7) compared with EGCG alone or PKC412 alone. For examples, the IC50 of EGCG alone for MOLM-13 cells was 15 µM, however, when combined with PKC412, the concentration of EGCG will reduce to 10 µM (with 5nM PKC412) and even 5 µM (with 7nM PKC412). Similarly, the IC50 of PKC412 alone for MOLM-13 cells was 20nM, however, when combined with EGCG, the concentration of PKC412 will remarkably reduce to 5nM (with 10 µM EGCG). It is important to note that green tea is now developing as a cancer preventive drug in the USA and Europe [23], [24]. It suggests that polyphenols of green tea could be promising candidates for treatment of AML or for combination with other drugs such as FLT3 inhibitors to improve the treatment efficacy.

Author Contributions

Conceived and designed the experiments: BTKL HTC KN YS TW. Performed the experiments: BTKL HTC MY. Analyzed the data: BTKL HTC MY KN YS TW. Contributed reagents/materials/analysis tools: YK YH. Wrote the paper: BTKL HTC YS TW.

Citation: Ly BTK, Chi HT, Yamagishi M, Kano Y, Hara Y, Nakano K, et al. (2013) Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-AML Cells. PLoS ONE 8(6): e66378. https://doi.org/10.1371/journal.pone.0066378

References

1. Dormer P, Lau B, Wilmanns W (1980) Kinetics of bone marrow cell production in human acute and chronic myeloid leukemias. Leuk Res 4: 231–237.

2. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, et al. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99: 4326–4335.

3. Maroc N, Rottapel R, Rosnet O, Marchetto S, Lavezzi C, et al. (1993) Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene 8: 909–918.

4. Drexler HG (1996) Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 10: 588–599.

5. Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, et al. (2004) Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 103: 1901–1908.

6. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, et al. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10: 1911–1918.

7. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, et al. (2001) Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 113: 983–988.

8. Spiekermann K, Bagrintseva K, Schoch C, Haferlach T, Hiddemann W, et al. (2002) A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood 100: 3423–3425.

9. Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, et al. (2009) Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 113: 4074–4077.

10. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, et al. (2001) FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97: 3589–3595.

11. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, et al. (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93: 3074–3080.

12. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, et al. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98: 1752–1759.

13. Reindl C, Bagrintseva K, Vempati S, Schnittger S, Ellwart JW, et al. (2006) Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood 107: 3700–3707.

14. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, et al. (2000) Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96: 3907–3914.

15. Choudhary C, Schwable J, Brandts C, Tickenbrock L, Sargin B, et al. (2005) AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 106: 265–273.

16. Grundler R, Miething C, Thiede C, Peschel C, Duyster J (2005) FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 105: 4792–4799.

17. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, et al. (2005) Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105: 1759–1767.

18. Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O’Brien S, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res 34: 752–756.

19. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 117: 3294–3301.

20. Kindler T, Lipka DB, Fischer T (2010) FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116: 5089–5102.

21. Ustun C, DeRemer DL, Jillella AP, Bhalla KN (2009) Investigational drugs targeting FLT3 for leukemia. Expert Opin Investig Drugs 18: 1445–1456.

22. Chen ZP, Schell JB, Ho CT, Chen KY (1998) Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett 129: 173–179.

23. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, et al. (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66: 1234–1240.

24. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, et al. (2009) Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2: 931–941.

25. Matsuo Y, MacLeod RA, Uphoff CC, Drexler HG, Nishizaki C, et al. (1997) Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia 11: 1469–1477.

26. Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, et al. (1987) Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 70: 192–199.

27. Iida S, Saito M, Okazaki T, Seto M, Yamamoto K, et al. (1992) Phenotypic and genotypic characterization of 14 leukemia and lymphoma cell lines with 11q23 translocations. Leuk Res 16: 1155–1163.

28. Taketani T, Taki T, Sugita K, Furuichi Y, Ishii E, et al. (2004) FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 103: 1085–1088.

29. Furukawa Y, Vu HA, Akutsu M, Odgerel T, Izumi T, et al. (2007) Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. Leukemia 21: 1005–1014.

30. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, et al. (1980) Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26: 171–176.

31. Chi HT, Vu HA, Iwasaki R, Thao le B, Hara Y, et al. (2009) Green tea (−)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells. Cancer Biol Ther 8: 1934–1939.

32. Kano Y, Ohnuma T, Okano T, Holland JF (1988) Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res 48: 351–356.

33. Kano Y, Akutsu M, Tsunoda S, Mori K, Suzuki K, et al. (1998) In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother Pharmacol 42: 91–98.

34. Yin Z, Henry EC, Gasiewicz TA (2009) (−)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry 48: 336–345.

35. Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, et al. (2002) Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia 16: 1535–1540.

36. Al Shaer L, Walsby E, Gilkes A, Tonks A, Walsh V, et al. (2008) Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Br J Haematol 141: 483–493.

37. Liang YC, Lin-shiau SY, Chen CF, Lin JK (1997) Suppression of extracellular signals and cell proliferation through EGF receptor binding by (−)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem 67: 55–65.

38. Guo S, Lu J, Subramanian A, Sonenshein GE (2006) Microarray-assisted pathway analysis identifies mitogen-activated protein kinase signaling as a mediator of resistance to the green tea polyphenol epigallocatechin 3-gallate in her-2/neu-overexpressing breast cancer cells. Cancer Res 66: 5322–5329.

39. Pianetti S, Guo S, Kavanagh KT, Sonenshein GE (2002) Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res 62: 652–655.

40. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, et al. (2004) VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 104: 788–794.

41. Ahn HY, Hadizadeh KR, Seul C, Yun YP, Vetter H, et al. (1999) Epigallocathechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172). Mol Biol Cell 10: 1093–1104.

42. Shimizu M, Shirakami Y, Sakai H, Tatebe H, Nakagawa T, et al. (2008) EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett 262: 10–18.

43. Li M, He Z, Ermakova S, Zheng D, Tang F, et al. (2007) Direct inhibition of insulin-like growth factor-I receptor kinase activity by (−)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev 16: 598–605.

44. Westerheide SD, Morimoto RI (2005) Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem 280: 33097–33100.

45. Welch WJ (1991) The role of heat-shock proteins as molecular chaperones. Curr Opin Cell Biol 3: 1033–1038.

46. McClellan AJ, Xia Y, Deutschbauer AM, Davis RW, Gerstein M, et al. (2007) Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 131: 121–135.

47. Falsone SF, Gesslbauer B, Tirk F, Piccinini AM, Kungl AJ (2005) A proteomic snapshot of the human heat shock protein 90 interactome. FEBS Lett 579: 6350–6354.

48. Kamal A, Boehm MF, Burrows FJ (2004) Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 10: 283–290.

49. Prodromou C, Roe SM, O’Brien R, Ladbury JE, Piper PW, et al. (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90: 65–75.

50. Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM (2000) The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 275: 37181–37186.

51. Bagatell R, Whitesell L (2004) Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 3: 1021–1030.

52. Terasawa K, Minami M, Minami Y (2005) Constantly updated knowledge of Hsp90. J Biochem 137: 443–447.

53. Li Y, Zhang T, Jiang Y, Lee HF, Schwartz SJ, et al. (2009) (−)-Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2. Mol Pharm 6: 1152–1159.